drugset
drugset / Trial / NCT04839562

A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in Adults

NCT04839562 ↗

Phase 2/3 Completed 66 enrolled Massachusetts General Hospital
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A double-blind, placebo controlled study of solriamfetol for adults age 18 to 65 with diagnosis of Attention Deficit Hyperactivity Disorder.

Timeline

Start
2021-08-06
Primary completion
2023-01-27
Completion
2023-01-27

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Solriamfetol Small molecule 75 mg Oral
Subject Solriamfetol Small molecule 150 mg Oral

Indications

attention deficit-hyperactivity disorder